Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytokinetics

39.48
+0.33000.84%
Post-market: 39.480.00000.00%16:07 EDT
Volume:1.07M
Turnover:41.98M
Market Cap:4.67B
PE:-7.50
High:39.53
Open:38.77
Low:38.41
Close:39.15
Loading ...

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
14 mins ago

Cytokinetics Director Cashes In on Stock Sale!

TIPRANKS
·
Yesterday

Cytokinetics’ Aficamten: A Promising Opportunity Amidst nHCM Treatment Challenges

TIPRANKS
·
16 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Dow, Nike, Coty

Reuters
·
16 Apr

Cytokinetics Is Maintained at Neutral by B of A Securities

Dow Jones
·
16 Apr

Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.

Dow Jones
·
15 Apr

Cytokinetics Shares Fall 1.4% After Rival Bristol Myers' Heart Drug Fails Trial

THOMSON REUTERS
·
15 Apr

BUZZ-Cytokinetics falls after rival Bristol Myers' heart drug fails trial

Reuters
·
15 Apr

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

Dow Jones
·
11 Apr

Cytokinetics CEO Cashes In on Stock Sale

TIPRANKS
·
11 Apr

Cytokinetics Price Target Maintained With a $78.00/Share by JMP Securities

Dow Jones
·
10 Apr

Optimistic Buy Rating on Cytokinetics Driven by Promising Aficamten Trial Outcomes

TIPRANKS
·
10 Apr

Top Executive Sells Thousands in Cytokinetics Stock!

TIPRANKS
·
09 Apr

Cytokinetics Price Target Maintained With a $72.00/Share by Needham

Dow Jones
·
08 Apr

Needham Sticks to Its Buy Rating for Cytokinetics (CYTK)

TIPRANKS
·
08 Apr

Cytokinetics Director Makes a Strategic Stock Move

TIPRANKS
·
05 Apr

Cytokinetics Price Target Maintained With a $78.00/Share by Citizens Capital Markets

Dow Jones
·
03 Apr

Cytokinetics: A Promising Investment with Aficamten’s Competitive Edge in HCM Treatment

TIPRANKS
·
03 Apr

BUZZ-Edgewise falls on safety, efficacy doubts for heart disease drug

Reuters
·
02 Apr

Cytokinetics CEO Makes Major Stock Move!

TIPRANKS
·
01 Apr